{"id":826511,"date":"2025-03-17T16:04:48","date_gmt":"2025-03-17T20:04:48","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-provide-business-update-and-fourth-quarter-and-full-year-2024-financial-results-on-march-25-2025\/"},"modified":"2025-03-17T16:04:48","modified_gmt":"2025-03-17T20:04:48","slug":"corvus-pharmaceuticals-to-provide-business-update-and-fourth-quarter-and-full-year-2024-financial-results-on-march-25-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-provide-business-update-and-fourth-quarter-and-full-year-2024-financial-results-on-march-25-2025\/","title":{"rendered":"Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025"},"content":{"rendered":"

\nCompany to host conference call and webcast at 4:30 pm ET \/ 1:30 pm PT
\n<\/h2>\n
\n

SOUTH SAN FRANCISCO, Calif., March 17, 2025 (GLOBE NEWSWIRE) — Corvus Pharmaceuticals, Inc.\u00a0(NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on March 25, 2025 at 4:30 pm ET (1:30 pm PT) to provide a business update and report fourth quarter and full year 2024 financial results.<\/p>\n

The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) or by clicking on this link<\/a> for instant telephone access to the event. The live webcast may be accessed via the investor relations<\/a> section of the Corvus website. A replay of the webcast will be available on Corvus\u2019 website for 90 days.<\/p>\n

\n About\u00a0Corvus Pharmaceuticals<\/strong>
\n
Corvus Pharmaceuticals\u00a0is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company\u2019s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit\u00a0www.corvuspharma.com<\/a>.<\/p>\n

\n INVESTOR CONTACT:<\/strong>
\n
Leiv Lea
Chief Financial Officer
Corvus Pharmaceuticals, Inc.
+1-650-900-4522
llea@corvuspharma.com<\/a><\/p>\n

\n MEDIA CONTACT:<\/strong>
\n
Sheryl Seapy
Real Chemistry
+1-949-903-4750
sseapy@realchemistry.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Company to host conference call and webcast at 4:30 pm ET \/ 1:30 pm PT SOUTH SAN FRANCISCO, Calif., March 17, 2025 (GLOBE NEWSWIRE) — Corvus Pharmaceuticals, Inc.\u00a0(NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on March 25, 2025 at 4:30 pm ET (1:30 pm PT) to provide a business update and report fourth quarter and full year 2024 financial results. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) or by clicking on this link for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the Corvus website. A replay of the webcast will be … <\/p>\n

Continue reading “Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-826511","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nCorvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-provide-business-update-and-fourth-quarter-and-full-year-2024-financial-results-on-march-25-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Company to host conference call and webcast at 4:30 pm ET \/ 1:30 pm PT SOUTH SAN FRANCISCO, Calif., March 17, 2025 (GLOBE NEWSWIRE) — Corvus Pharmaceuticals, Inc.\u00a0(NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on March 25, 2025 at 4:30 pm ET (1:30 pm PT) to provide a business update and report fourth quarter and full year 2024 financial results. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) or by clicking on this link for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the Corvus website. A replay of the webcast will be … Continue reading "Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-provide-business-update-and-fourth-quarter-and-full-year-2024-financial-results-on-march-25-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-17T20:04:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTA3MCM2ODA1OTY3IzIwMjU5OTM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corvus-pharmaceuticals-to-provide-business-update-and-fourth-quarter-and-full-year-2024-financial-results-on-march-25-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corvus-pharmaceuticals-to-provide-business-update-and-fourth-quarter-and-full-year-2024-financial-results-on-march-25-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025\",\"datePublished\":\"2025-03-17T20:04:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corvus-pharmaceuticals-to-provide-business-update-and-fourth-quarter-and-full-year-2024-financial-results-on-march-25-2025\\\/\"},\"wordCount\":231,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corvus-pharmaceuticals-to-provide-business-update-and-fourth-quarter-and-full-year-2024-financial-results-on-march-25-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NTA3MCM2ODA1OTY3IzIwMjU5OTM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corvus-pharmaceuticals-to-provide-business-update-and-fourth-quarter-and-full-year-2024-financial-results-on-march-25-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corvus-pharmaceuticals-to-provide-business-update-and-fourth-quarter-and-full-year-2024-financial-results-on-march-25-2025\\\/\",\"name\":\"Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corvus-pharmaceuticals-to-provide-business-update-and-fourth-quarter-and-full-year-2024-financial-results-on-march-25-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corvus-pharmaceuticals-to-provide-business-update-and-fourth-quarter-and-full-year-2024-financial-results-on-march-25-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NTA3MCM2ODA1OTY3IzIwMjU5OTM=\",\"datePublished\":\"2025-03-17T20:04:48+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corvus-pharmaceuticals-to-provide-business-update-and-fourth-quarter-and-full-year-2024-financial-results-on-march-25-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corvus-pharmaceuticals-to-provide-business-update-and-fourth-quarter-and-full-year-2024-financial-results-on-march-25-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corvus-pharmaceuticals-to-provide-business-update-and-fourth-quarter-and-full-year-2024-financial-results-on-march-25-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NTA3MCM2ODA1OTY3IzIwMjU5OTM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NTA3MCM2ODA1OTY3IzIwMjU5OTM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corvus-pharmaceuticals-to-provide-business-update-and-fourth-quarter-and-full-year-2024-financial-results-on-march-25-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-provide-business-update-and-fourth-quarter-and-full-year-2024-financial-results-on-march-25-2025\/","og_locale":"en_US","og_type":"article","og_title":"Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025 - Market Newsdesk","og_description":"Company to host conference call and webcast at 4:30 pm ET \/ 1:30 pm PT SOUTH SAN FRANCISCO, Calif., March 17, 2025 (GLOBE NEWSWIRE) — Corvus Pharmaceuticals, Inc.\u00a0(NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on March 25, 2025 at 4:30 pm ET (1:30 pm PT) to provide a business update and report fourth quarter and full year 2024 financial results. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) or by clicking on this link for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the Corvus website. A replay of the webcast will be … Continue reading \"Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-provide-business-update-and-fourth-quarter-and-full-year-2024-financial-results-on-march-25-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-17T20:04:48+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTA3MCM2ODA1OTY3IzIwMjU5OTM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-provide-business-update-and-fourth-quarter-and-full-year-2024-financial-results-on-march-25-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-provide-business-update-and-fourth-quarter-and-full-year-2024-financial-results-on-march-25-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025","datePublished":"2025-03-17T20:04:48+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-provide-business-update-and-fourth-quarter-and-full-year-2024-financial-results-on-march-25-2025\/"},"wordCount":231,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-provide-business-update-and-fourth-quarter-and-full-year-2024-financial-results-on-march-25-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTA3MCM2ODA1OTY3IzIwMjU5OTM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-provide-business-update-and-fourth-quarter-and-full-year-2024-financial-results-on-march-25-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-provide-business-update-and-fourth-quarter-and-full-year-2024-financial-results-on-march-25-2025\/","name":"Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-provide-business-update-and-fourth-quarter-and-full-year-2024-financial-results-on-march-25-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-provide-business-update-and-fourth-quarter-and-full-year-2024-financial-results-on-march-25-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTA3MCM2ODA1OTY3IzIwMjU5OTM=","datePublished":"2025-03-17T20:04:48+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-provide-business-update-and-fourth-quarter-and-full-year-2024-financial-results-on-march-25-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-provide-business-update-and-fourth-quarter-and-full-year-2024-financial-results-on-march-25-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-provide-business-update-and-fourth-quarter-and-full-year-2024-financial-results-on-march-25-2025\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTA3MCM2ODA1OTY3IzIwMjU5OTM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTA3MCM2ODA1OTY3IzIwMjU5OTM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-provide-business-update-and-fourth-quarter-and-full-year-2024-financial-results-on-march-25-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/826511","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=826511"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/826511\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=826511"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=826511"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=826511"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}